"Colitis, Ulcerative" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.
| Descriptor ID |
D003093
|
| MeSH Number(s) |
C06.405.205.265.231 C06.405.205.731.249 C06.405.469.158.188.231 C06.405.469.432.249
|
| Concept/Terms |
Colitis, Ulcerative- Colitis, Ulcerative
- Idiopathic Proctocolitis
- Ulcerative Colitis
- Colitis Gravis
- Inflammatory Bowel Disease, Ulcerative Colitis Type
|
Below are MeSH descriptors whose meaning is more general than "Colitis, Ulcerative".
Below are MeSH descriptors whose meaning is more specific than "Colitis, Ulcerative".
This graph shows the total number of publications written about "Colitis, Ulcerative" by people in this website by year, and whether "Colitis, Ulcerative" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 5 | 3 | 8 |
| 1997 | 3 | 0 | 3 |
| 1998 | 7 | 2 | 9 |
| 1999 | 4 | 2 | 6 |
| 2000 | 6 | 0 | 6 |
| 2001 | 8 | 2 | 10 |
| 2002 | 6 | 1 | 7 |
| 2003 | 11 | 1 | 12 |
| 2004 | 12 | 0 | 12 |
| 2005 | 6 | 4 | 10 |
| 2006 | 15 | 1 | 16 |
| 2007 | 12 | 4 | 16 |
| 2008 | 11 | 2 | 13 |
| 2009 | 10 | 3 | 13 |
| 2010 | 9 | 0 | 9 |
| 2011 | 24 | 3 | 27 |
| 2012 | 11 | 1 | 12 |
| 2013 | 14 | 2 | 16 |
| 2014 | 8 | 1 | 9 |
| 2015 | 7 | 4 | 11 |
| 2016 | 21 | 5 | 26 |
| 2017 | 17 | 4 | 21 |
| 2018 | 14 | 1 | 15 |
| 2019 | 20 | 4 | 24 |
| 2020 | 24 | 2 | 26 |
| 2021 | 27 | 2 | 29 |
| 2022 | 29 | 0 | 29 |
| 2023 | 26 | 0 | 26 |
| 2024 | 22 | 5 | 27 |
| 2025 | 30 | 1 | 31 |
| 2026 | 15 | 1 | 16 |
To return to the timeline,
click here.
Below are the most recent publications written about "Colitis, Ulcerative" by people in Profiles.
-
Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trials. Inflamm Bowel Dis. 2026 Jul 01; 32(7):1235-1247.
-
Global Roll-Out and Continued Multi-Site Validation of the Artificial Intelligence Histology Instrument for Qualitative Assessment of Histopathology in Ulcerative Colitis. United European Gastroenterol J. 2026 Jul; 14(6):e70227.
-
Combining Guselkumab with Upadacitinib Is Safe and Effective in the Treatment of Medically Complex Inflammatory Bowel Disease. Dig Dis Sci. 2026 Oct; 71(10):4831-4841.
-
Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial. J Crohns Colitis. 2026 May 08; 20(5).
-
Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis. Inflamm Bowel Dis. 2026 May 01; 32(5):954-962.
-
Spatial transcriptomics atlas of inflammatory bowel disease to guide implementation in research consortiums and clinical trials. Nat Commun. 2026 Apr 28; 17(1).
-
The Risk of Relapse Associated With Discontinuation of 5-Aminosalicylates in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis. 2026 Apr 01; 32(4):661-676.
-
Impact of Immunogenicity on Clinical Outcomes in Patients With Moderate-to-Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY Trials. United European Gastroenterol J. 2026 Apr; 14(3):e70205.
-
Multiomic characterisation of the clinical efficacy of guselkumab induction therapy in ulcerative colitis. BMJ Open Gastroenterol. 2026 Mar 23; 13(1).
-
Correlation between patient-determined inflammatory bowel disease severity and the inflammatory bowel disease severity index. N Z Med J. 2026 Mar 13; 139(1631):76-92.